These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2696371)

  • 1. Treatment of uraemic anaemia with recombinant human erythropoietin.
    Ponticelli C; Casati S; Campise M
    Adv Exp Med Biol; 1989; 260():53-9. PubMed ID: 2696371
    [No Abstract]   [Full Text] [Related]  

  • 2. Correction of anaemia with recombinant human erythropoietin.
    Ponticelli C; Casati S
    Nephron; 1989; 52(3):201-8. PubMed ID: 2662045
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant human erythropoietin therapy. Part I: clinical issues.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):1-34. PubMed ID: 2928605
    [No Abstract]   [Full Text] [Related]  

  • 4. Aluminium interference in the treatment with recombinant human erythropoietin.
    Casati S; Campise M; Ponticelli C
    Contrib Nephrol; 1990; 87():87-94. PubMed ID: 2093544
    [No Abstract]   [Full Text] [Related]  

  • 5. rhEPO treatment of anemia in uremic patients.
    Bommer J; Barth HP; Schwöbel B
    Contrib Nephrol; 1990; 87():59-67. PubMed ID: 2093542
    [No Abstract]   [Full Text] [Related]  

  • 6. Arterial hypertension in uraemic patients treated with erythropoietin.
    Kokot F; Wiecek A
    Nephron; 1995; 71(2):127-32. PubMed ID: 8569941
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease.
    Koene RA; Frenken LA
    Kidney Int Suppl; 1992 Oct; 38():S142-7. PubMed ID: 1405365
    [No Abstract]   [Full Text] [Related]  

  • 8. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin.
    Moia M; Mannucci PM; Vizzotto L; Casati S; Cattaneo M; Ponticelli C
    Lancet; 1987 Nov; 2(8570):1227-9. PubMed ID: 2890852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of erythropoietin therapy on the red cell volume of uraemic and non-uraemic rats.
    Anagnostou A; Barone J; Kedo A; Fried W
    Br J Haematol; 1977 Sep; 37(1):85-91. PubMed ID: 588481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
    Brown CD; Friedman EA
    Contrib Nephrol; 1991; 88():182-9; discussion 190-1. PubMed ID: 2040181
    [No Abstract]   [Full Text] [Related]  

  • 11. L-Carnitine effects on anemia in uremic rats treated with erythropoietin.
    Azzadin A; Wollny T; Pawlak R; Malyszko JS; Malyszko J; Myśliwiec M; Buczko W
    Nephron; 1999; 83(4):370-1. PubMed ID: 10575305
    [No Abstract]   [Full Text] [Related]  

  • 12. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.
    Casati S; Passerini P; Campise MR; Graziani G; Cesana B; Perisic M; Ponticelli C
    Br Med J (Clin Res Ed); 1987 Oct; 295(6605):1017-20. PubMed ID: 3120854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does anemia correction by rHuEPO improve uremic cardiopathy?
    Carletti P; Bibiano L; Boggi R; Taruscia D; Mioli V
    Kidney Int Suppl; 1993 Jun; 41():S70-1. PubMed ID: 8320949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin and high flux haemodiafiltration.
    Lippi A; Rindi P; Baronti R; Caprioli R; Favilla G; Palmarini D; Cioni L
    Nephrol Dial Transplant; 1995; 10 Suppl 6():51-4. PubMed ID: 8524496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients.
    Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Mombelloni S; Visioli O; Maiorca R
    Nephrol Dial Transplant; 1991; 6(1):31-7. PubMed ID: 1829146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure.
    Savica V; Costantino G; Monardo P; Bellinghieri G
    Am J Nephrol; 1995; 15(1):10-4. PubMed ID: 7872358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of treating uremia anemia with human recombinant erythropoietin].
    Litwin M; Grenda R; Jelonek A
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):132-4. PubMed ID: 8090664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of erythropoietin administration in uremia.
    Gurland HJ; Samtleben W; Schmidt B
    Contrib Nephrol; 1989; 70():172-7. PubMed ID: 2670428
    [No Abstract]   [Full Text] [Related]  

  • 19. [The treatment of renal anemia].
    Koch KM
    Verh Dtsch Ges Inn Med; 1989; 95():246-8. PubMed ID: 2603482
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term persistence of improvement of renal anaemia in spite of discontinued erythropoietin treatment.
    Wiecek A; Kokot F; Marcinkowski W
    Nephron; 1995; 69(4):489-90. PubMed ID: 7777122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.